Published in Cancer Prev Res (Phila) on May 01, 2013
Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget (2016) 0.86
Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med (1989) 11.07
Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol (1980) 2.43
Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res (2000) 2.34
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1995) 2.09
Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol (2003) 1.94
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst (1998) 1.78
Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med (1995) 1.58
Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila) (2011) 1.57
Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila) (2013) 1.50
Oral leukoplakia in relation to tobacco habits. A ten-year follow-up study of Bombay policemen. Oral Surg Oral Med Oral Pathol (1972) 1.47
Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers of Gujarat, India. Cancer (1976) 1.40
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res (Phila) (2009) 1.31
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol (2008) 1.25
Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res (2000) 1.19
Subjectivity in evaluating oral epithelial dysplasia, carcinoma in situ and initial carcinoma. J Oral Pathol (1985) 1.18
p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol (1998) 1.18
Follow-up studies in oral leukoplakia. J Maxillofac Surg (1977) 1.15
Chemopreventive agents: protease inhibitors. Pharmacol Ther (1998) 1.13
The importance of using scientific principles in the development of medicinal agents from plants. Acad Med (2001) 0.97
Dietary chemopreventive phytochemicals: too little or too much? Cancer Prev Res (Phila) (2009) 0.97
Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev (2000) 0.96
Role of smoking in floor of the mouth leukoplakias. J Oral Pathol (1972) 0.94
Inhibition of oral carcinogenesis by a protease inhibitor. J Natl Cancer Inst (1986) 0.89
Oral premalignant lesions: any progress with systemic therapies? Curr Opin Oncol (2012) 0.87
Levels of proteolytic activities as intermediate marker endpoints in oral carcinogenesis. Cancer Epidemiol Biomarkers Prev (1995) 0.84
Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk Inhibitor. Cancer Epidemiol Biomarkers Prev (1999) 0.84
Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA. Nutr Cancer (1993) 0.83
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res (2004) 2.95
Focus on head and neck cancer. Cancer Cell (2004) 2.11
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol (2003) 1.78
High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) (2009) 1.59
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs (2007) 1.53
Akt activation correlates with adverse outcome in tongue cancer. Cancer (2005) 1.20
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer (2010) 1.15
Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) (2011) 1.13
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer (2005) 1.05
Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst (2003) 1.00
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys (2004) 0.91
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila) (2009) 0.90
Postoperative radiotherapy for maxillary sinus cancer: long-term outcomes and toxicities of treatment. Int J Radiat Oncol Biol Phys (2007) 0.87
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs (2010) 0.87
Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis. Cancer (2005) 0.84
The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park) (2011) 0.77
Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) (2003) 0.75
Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. J Thorac Imaging (2017) 0.75
Outcomes of patients with tonsillar carcinoma treated with post-tonsillectomy radiation therapy. Head Neck (2010) 0.75
Phosphatidykinosital 3-kinase and mammalian target of rapamycin pathway in non-small-cell lung cancer. J Thorac Oncol (2012) 0.75
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer (2003) 0.75
Targeted Therapy and Imaging Findings. J Thorac Imaging (2017) 0.75